Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Coya Therapeutics (NASDAQ:COYA) from a "hold" to a "sell" rating in a report released Saturday.
• Despite the downgrade, five analysts still rate the stock "Buy" vs one "Sell," giving a consensus rating of Moderate Buy and an average target price of $16.00.
• Coya reported a quarterly loss of $0.34 per share vs. an expected -$0.08, posted a negative net margin of 267%, and is trading around $4.21 with a market capitalization near $98.8 million.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

A number of other equities research analysts have also recently weighed in on COYA. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, February 2nd. D. Boral Capital reissued a "buy" rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.

Coya Therapeutics Stock Performance

Coya Therapeutics stock opened at $4.21 on Friday. The company has a 50-day simple moving average of $4.69 and a 200-day simple moving average of $5.53. The firm has a market capitalization of $98.77 million, a P/E ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a one year low of $3.94 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. As a group, sell-side analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new stake in Coya Therapeutics during the 4th quarter worth about $47,000. Occudo Quantitative Strategies LP purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $66,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics in the third quarter worth about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Coya Therapeutics in the fourth quarter worth approximately $81,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.